TPTiffany Patterson

Tiffany Patterson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tiffany Patterson has a total of 475 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effects of Transcatheter Tricuspid Edge‐to‐Edge Repair on Right Heart Dimension and Function

    by Stephanie Brunner, Lukas Stolz, Karl‐Patrik Kresoja, Jennifer von Stein, Vera Fortmeier, Benedikt Koell, Wolfgang Rottbauer, Mohammad Kassar, Bjoern Goebel, Paolo Denti, et al.

    Background: Transcatheter tricuspid edge‐to‐edge repair (T‐TEER) has developed as a treatment option for patients experiencing severe tricuspid regurgitation. T‐TEER consistently reduces tricuspid regurgitation, but data on subsequent right heart remodeling remain limited. The aim of this study was to evaluate changes in right heart dimension and function after T‐TEER using extended echocardiographic follow‐up. Methods: The study was based on the international EuroTR (European Registry of Transcatheter Repair for Tricuspid Regurgitation), including patients undergoing T‐TEER between 2016 and 2024 at 18 European centers. Eligible were patients with available baseline and follow‐up (≥90 days postprocedure) echocardiographic assessment. Results: A total of 699 patients (mean age, 78±8 years; 56% women) were included in the analysis. Echocardiographic follow‐up was performed at a median of 407 days (interquartile range, 205–801 days). Right heart dimensions significantly decreased: right ventricular (RV) midventricular diameter from 40.2±8.9 to 37.1±8.4 mm ( P 2 ( P P P <0.001) was observed. Conclusions: In the subset of surviving patients with available echocardiographic follow‐up, treatment with T‐TEER led to favorable long‐term changes with reduced RV dimension, associated with procedural success. RV function modestly decreased, likely reflecting normalization after volume unloading.

  • Open Access

    Impact of concomitant left-sided valve disease on outcomes following tricuspid valve transcatheter edge-to-edge repair: insights from EuroTR

    by Jonas Gmeiner, Lukas Stolz, Karl-Patrik Kresoja, Jennifer von Stein, Vera Fortmeier, Christoph Pauschinger, Wolfgang Rottbauer, Mohammad Kassar, Bjoern Goebel, Paolo Denti, et al.

    Introduction: The impact of coexisting left-sided valvular heart disease (VHD) on clinical outcomes following tricuspid valve edge-to-edge repair (T-TEER) for tricuspid regurgitation (TR) remains unclear, particularly under real-world conditions. To evaluate the prevalence and prognostic impact of concomitant left-sided VHD in patients undergoing T-TEER. Methods: This study included all patients undergoing T-TEER from the European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR; NCT06307262) with complete echocardiographic data on left-sided valve disease. Study endpoints included survival and heart failure hospitalizations (HFH) at 2 years, NYHA functional class, and TR reduction. Results: Among a total of 1647 eligible patients, 95.8%, 35.6%, and 3.8% had ≥mild, moderate, and severe concomitant VHD, respectively. Moderate or higher VHD was associated with a significantly reduced 2-year survival (P < .001) and reduced 2-year HFH-free survival (P = .005). Multivariate regression analysis confirmed ≥ moderate VHD to be an independent predictor of mortality (hazard ratio 1.54, 95% CI 1.21–1.96, P < .001). Despite worse TR and NYHA functional class at baseline in patients with ≥moderate VHD, T-TEER was associated with a significant TR reduction (P < .001) and symptomatic improvement (P < .001). Conclusion: Concomitant left-sided VHD is common among patients undergoing T-TEER and is independently associated with worse survival and higher rates of HFH. Nevertheless, T-TEER provides meaningful symptomatic benefit and durable TR reduction in patients with and without VHD burden.


  • Open Access

    Combined transcatheter mitral and tricuspid edge-to-edge repair or tricuspid edge-to-edge repair alone in moderate mitral regurgitation: a propensity-matched analysis

    by Mohammad Kassar, Fabien Praz, Muhammed Gerçek, Vera Fortmeier, Karl-Patrik Kresoja, Jennifer von Stein, Christoph Pauschinger, Wolfgang Rottbauer, Bjoern Goebel, Paolo Denti, et al.

    Background and Aims: The coexistence of moderate mitral regurgitation (MR) and severe tricuspid regurgitation (TR) is common, yet evidence guiding optimal management remains limited. Transcatheter edge-to-edge repair (TEER) of both valves—performed either sequentially or in combination—has emerged as a potential therapeutic strategy. This study aimed to assess the prognostic impact of moderate MR in patients undergoing tricuspid TEER (T-TEER) for severe TR and to evaluate whether concomitant mitral TEER (M-TEER) improves clinical outcomes. Methods: Data from the EuroTR registry (2016–25) were analysed, including patients with severe TR treated with T-TEER. Outcomes were compared between patients with untreated moderate MR and those who underwent concomitant M-TEER using propensity score matching (PSM). The primary endpoint was all-cause mortality at 2 years. Secondary endpoints included New York Heart Association (NYHA) class, 6 min walk distance (6MWD), TR severity, and heart failure rehospitalizations. Results: Among 3100 patients, 30% had moderate MR, which was associated with higher 2-year mortality (23% vs 37%, p<0.0001). After PSM, 217 matched patients treated with concomitant M-TEER had greater TR reduction (−1.9 vs −1.6 grades, P = .001), better NYHA improvement, and increased 6MWD at follow-up. Survival was higher in the combined treatment group (87% vs 76% at 1 year; 81% vs 70% at 2 years, P = .005). In a multivariable analysis, moderate MR predicted increased mortality [hazard ratio (HR) 1.81, P = .005), while combined M-TEER predicted better survival (HR 0.46, P < .0001). Conclusions: Moderate MR predicts impaired prognosis in patients undergoing T-TEER for treatment of severe TR. Concomitant M-TEER is associated with improved survival and functional outcomes in this population with multivalve disease. These findings are hypothesis-generating and need to be tested in a dedicated randomized controlled trial.


  • Open Access

    Impact of Extravalvular Remodeling on Wearable Smartwatch‐Recorded Physical Activity in Patients Undergoing Transcatheter Aortic Valve Implantation for Severe Symptomatic Aortic Stenosis

    by Vitaliy Androshchuk, Edouard Long, Omar Chehab, Joshua Wilcox, Benedict McDonaugh, Ronak Rajani, Bernard Prendergast, Tiffany Patterson, Simon Redwood

    Background: Wearable smartwatches enable objective quantification of physical activity. This study evaluated the association of extravalvular cardiac damage in aortic stenosis with smartwatch‐recorded physical activity before and after transcatheter aortic valve implantation (TAVI). Methods: Patients with severe symptomatic aortic stenosis were dichotomized into cardiac damage stages 0 to 2 (left‐heart dysfunction) and stages 3 to 4 (pulmonary/right‐heart dysfunction) by echocardiography. All patients received a Fitbit smartwatch for 7 days of continuous monitoring before transcatheter aortic valve implantation and at 6‐month follow‐up. Regression models determined significant predictors of total daily step count and moderate to vigorous physical activity (MVPA). Results: Within the study cohort (stages 0–2: 43 [50.6%]; stages 3–4: 42 [49.4%]), all patients showed significant improvement in physical activity from baseline to follow‐up (all P P P =0.002; MVPA: β=−12.9 [95% CI, −24.3 to −1.5], P =0.027) and follow‐up (step count: β=−1438.1 [95% CI, −2453.9 to −422.3], P =0.006; MVPA: β=−27.4 [95% CI, −47.7 to −7.1], P =0.009), as well as less improvement in MVPA (β=−14.5 [95% CI, −28.4 to −0.48], P =0.043) after transcatheter aortic valve implantation. Conclusions: The extent of cardiac damage before transcatheter aortic valve implantation has an important impact on physical activity, both at baseline and following intervention. Future studies should examine whether smartwatch‐measured activity predicts death across cardiac damage stages and whether cardiac rehabilitation improves outcomes in aortic stenosis with advanced remodeling.

  • Open Access

    Point-of-care testing for pre-hospital stratification after out-of-hospital cardiac arrest: the RAPID-MIRACLE study

    by Muhamad Abd Razak, Prajith Jeyaprakash, Michael McGarvey, John Hodsoll, Evan Ansell, Roman Roy, Krishnaraj Rathod, Shayna Chotai, Fiyyaz Ahmed-Jushuf, Oliver Rees, et al.

    Aims: Out-of-hospital cardiac arrest (OHCA) has high mortality, and outcomes remain heterogeneous despite guidelines recommending universal conveyance to cardiac arrest centres. Early pre-hospital risk stratification may identify patients most likely to benefit. The pre-hospital utility of MIRACLE2 is unknown, so we evaluated the feasibility of rapid point-of-care testing to enable calculation of the MIRACLE2 score after return of spontaneous circulation (ROSC). Methods and results: RAPID-MIRACLE was a prospective, multi-centre observational study conducted across London with the London Ambulance Service. Adult patients with suspected cardiac aetiology OHCA achieving sustained ROSC were enrolled. Pre-hospital point-of-care venous blood-gas sampling was performed with results blinded to receiving hospitals. We evaluated ROSC-MIRACLE2 incorporating post-ROSC pH, compared with a modified MIRACLE2 excluding pH (pre-MIRACLE2) and standard MIRACLE2 calculated on hospital admission. The primary outcome was poor neurological outcome at 30 days, defined as cerebral performance category (CPC) 3–5. Among 292 patients, 48% had poor neurological outcome. ROSC-MIRACLE2 demonstrated excellent discrimination [area under the receiver operating characteristic curve (AUC) 0.89 (95% CI 0.85–0.92)], comparable to pre-MIRACLE2 [AUC 0.88 (95% CI 0.84–0.92)], and admission MIRACLE2 [AUC 0.89 (95% CI 0.85–0.92)]. For ROSC-MIRACLE2, a threshold 0–2, the negative predictive value for good outcome was 0.89 (0.82–0.94). At a threshold ≥5, the positive predictive value was 0.88 (0.82–0.94). In a multi-variable regression model, post-ROSC pH was independently associated with poor neurological outcome and less than 3% of patients with a ROSC pH <7.00 had good neurological outcome. Conclusion: In this study, pre-hospital application of ROSC-MIRACLE2 enables early neurological risk stratification following resuscitated OHCA. Point-of-care pH improves prognostic precision, but is constrained by feasibility, whilst the simplified pre-MIRACLE2 score is more practical with comparable performance. Integration into OHCA care pathways may improve patient stratification and resource utilization but requires further study.


  • Open Access

    Invasive Hemodynamics and Risk Stratification in T-TEER: Moving Beyond ESC Thresholds - EuroTR Registry Insights

    by Giulia Masiero, Federico Arturi, Sara Ceni, Andrea Panza, Karl-Patrik Kresoja, Jennifer von Stein, Vera Fortmeier, Benedikt Koell, Wolfgang Rottbauer, Mohammad Kassar, et al.

    BACKGROUND: Right heart catheterization plays a pivotal role in the preprocedural evaluation of patients considered for transcatheter tricuspid valve edge-to-edge repair. This study aimed to explore the potential impact of hemodynamic parameters obtained through right heart catheterization on patient-centered outcomes. METHODS: This study represents a subanalysis from the multicenter EuroTR registry (European Registry of Transcatheter Repair for Tricuspid Regurgitation). Patients with invasive hemodynamic data who underwent isolated transcatheter tricuspid valve edge-to-edge repair for significant tricuspid regurgitation were included. Outcomes of interest were a composite of 2-year all-cause death or hospitalization for heart failure (HFH) and a patient-centered composite of 6-month all-cause mortality, HFH, New York Heart Association class IV/worsening New York Heart Association class compared with baseline. Secondary outcome included postprocedural New York Heart Association class improvement. RESULTS: Seven hundred and eleven patients were included in the analysis. Two-year survival free from death and HFH was 63%. Optimal prognostic thresholds identified for death and HFH at 2 years were: mean pulmonary artery pressure≥32 mm Hg, pulmonary capillary wedge pressure (PCWP)≥20 mm Hg, and pulmonary vascular resistance≥5 wood units (WU). The early patient-centered composite outcome occurred in 25% of cases. PCWP≥20 mm Hg was independently associated with an early clinical deterioration (hazard ratio, 2.77 [95% CI, 1.47–5.28]; P P =0.04). No invasive parameter was associated with residual tricuspid regurgitation ≥3+. New York Heart Association class improved significantly throughout the follow-up ( P P =0.04) or PCWP ( P <0.01) experienced less symptomatic benefit. CONCLUSIONS: In patients undergoing transcatheter tricuspid valve edge-to-edge repair, invasive hemodynamics—especially elevated PCWP—are independently associated with early patient-centered outcomes and late adverse clinical events. Despite overall improvement of the functional status and no impact on residual tricuspid regurgitation, patients with higher mean pulmonary artery pressure or PCWP benefit less. These findings support the role of comprehensive right heart catheterization in preprocedural risk stratification. REGISTRATION: URL: https://clinicaltrials.gov ; Unique identifier: NCT06307262.


  • Transcatheter Edge-to-Edge Repair in Degenerative Mitral Regurgitation

    by Tiffany Patterson, Rea Ganatra, Simon Redwood

  • Open Access

    Expedited transfer to emergency department vs. cardiac catheter laboratory in a cardiac arrest centre for non-ST-elevation out-of-hospital cardiac arrest: ARREST trial as-treated analysis

    by Tiffany Patterson, Gavin D Perkins, Matthew Dodd, Alexander Perkins, Adam Mellett-Smith, Rachael T Fothergill, Tim Clayton, Richard Evans, Steven Robertson, Matthew Kwok, et al.

    Aims: The ARREST trial demonstrated that in adult patients, transfer to a cardiac catheter laboratory in a cardiac arrest centre (CAC) following resuscitated out-of-hospital cardiac arrest (OHCA) without ST-elevation did not reduce deaths at 30 days compared with delivery to the geographically closest emergency department (standard care). More than half of the CACs had a co-located emergency department to which patients were delivered as part of the standard care arm, which may have influenced outcomes. Aims: We performed a pre-specified as-treated analysis to determine if a CAC and the location patients were delivered to, either emergency department or cardiac catheter laboratory, reduced deaths. Methods and results: Patients (aged ≥18 years) with resuscitated OHCA without ST elevation who were enrolled in the ARREST trial were grouped according to the location they were to delivered to– either an emergency department with or without a co-located CAC or a cardiac catheter laboratory within a CAC—at one of 35 hospitals in London, UK—by London Ambulance Service irrespective of randomized allocation. The as-treated population was therefore analysed as one of three groups: 1) emergency department in a CAC, 2) direct to a cardiac catheter laboratory in a CAC, and 3) emergency department in a non-CAC. The primary outcome of the trial was all-cause mortality at 30 days. Secondary outcomes included all-cause mortality at 3 months and neurological outcome at discharge and 3 months. A pre-specified analysis adjusting for age, sex, initial shockable rhythm, witnessed cardiac arrest, bystander CPR, the time from cardiac arrest until ROSC, and location of cardiac arrest was performed in the as-treated groups. Between 15 January 2018 and 1 December 2022, a total of 862 participants were enrolled into the trial. Data for the primary outcome for this analysis were available in 818/862 (94.9%). Patients delivered to an ED in a CAC had fewer deaths at 30 days compared with the ED in a non-CAC group (83/182, 45.6% vs. 178/233, 76.4%; adjusted OR 0.43, 95% CI 0.24 to 0.76; P = 0.0039). Patients delivered to a cardiac catheter laboratory in a CAC also had fewer deaths compared with the ED in a non-CAC group, but there was no statistical difference (250/403, 62.0%: adjusted OR 0.72, 95% CI 0.44 to 1.18; P = 0.19). Survival with a favourable neurological outcome at hospital discharge occurred in 88/177 (49.7%) of the ED in a CAC group, 130/406 (32%) of the catheter laboratory in a CAC group, and 42/228 (18.4%) of the ED in a non-CAC group. Conclusion: In this as-treated analysis of the ARREST trial, in adult patients with resuscitated OHCA without ST-elevation, we observed a lower 30-day mortality and favourable neurological outcomes following delivery to an ED in a CAC and cardiac catheter laboratory in CAC, when compared with delivery to ED in a non-CAC.


  • Open Access

    Multimodality Imaging in Valvular Structural Interventions

    by Karine Grigoryan, Camelia Demetrescu, Ioannis Kasouridis, Olukayode Abiola, Pier Giorgio Masci, Didem Oguz, Giulia Benedetti, Sze Mun Mak, Purvi Parwani, Rebecca Preston, et al.

    Structural valvular interventions have skyrocketed in the past decade with new devices becoming available and indications for patients who would previously have been deemed inoperable. Furthermore, while echocardiography is the main imaging tool and the first line for patient screening, cardiac magnetic resonance and CT are now essential tools in pre-planning and post-procedural follow-up. This review aims to address imaging modalities and their scope in aortic, mitral and tricuspid structural valvular interventions, including multimodality imaging. Pulmonary valve procedures, which are mostly carried out in patients with congenital problems, are discussed. This article presents a guide on individualised imaging approaches on each of the available interventional procedures.